Literature DB >> 8620412

Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute.

J D Wilkes1, P Fidias, L Vaickus, R P Perez.   

Abstract

BACKGROUND: Malignancy-related pericardial effusions may represent a terminal event in patients with therapeutically unresponsive disease. However, select patients with malignancies sensitive to available therapies may achieve significant improvement in palliation and long term survival with prompt recognition and appropriate intervention.
METHODS: From 1968 to 1994, 150 invasive procedures were performed for the treatment or diagnosis of pericardial effusion in 127 patients with underlying malignancies. These cases were reviewed retrospectively to best identify the clinical features, appropriate diagnostic workup, and optimal therapy for this complication of malignancy.
RESULTS: Dyspnea (81%) and an abnormal pulsus paradoxus (32%) were the most common symptoms. Echocardiography had a 96% diagnostic accuracy. Cytology and pericardial biopsy had sensitivities of 90% and 56%, respectively. Fifty-five percent of all effusions were malignant comprising 71% of adenocarcinomas of the lung, breast, esophagus, and unknown primary site. In 57 patients, a malignant effusion could not be determined, and no definitive etiology could be established for 74% of these effusions. Radiation-induced, infectious, and hemorrhagic pericarditis each were identified in fewer than 5% of cases.
CONCLUSIONS: Subxyphoid pericardiotomy proved to be a safe and effective intervention that successfully relieved pericardial effusions in 99% of cases with recurrence and reoperation rates of 9% and 7%, respectively. Survival most closely was related to the extent of disease and its inherent chemo-/radiosensitivity, with 72% of the patients who survived longer than 1 year having breast cancer, leukemia, or lymphoma.

Entities:  

Mesh:

Year:  1995        PMID: 8620412     DOI: 10.1002/1097-0142(19951015)76:8<1377::aid-cncr2820760813>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  26 in total

1.  Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids.

Authors:  Sophya Konstantinovsky; Ben Davidson; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2012-04-04       Impact factor: 5.150

2.  Successful treatment of malignant pericardial effusion, using weekly paclitaxel, in a patient with breast cancer.

Authors:  Takahiro Einama; Kazuhiko Sato; Hitoshi Tsuda; Hidetaka Mochizuki
Journal:  Int J Clin Oncol       Date:  2006-10       Impact factor: 3.402

3.  Pulmonary hypertension concurrent with pericardial effusion and superior vena cava syndrome: who is the initiator?

Authors:  Bei-Ning Wang; Yu-Xi Li; Wei Ma; Song-Yun Chu; Zhi-Hao Liu; Wen-Hui Ding; Jian-Ping Li
Journal:  J Geriatr Cardiol       Date:  2020-11-28       Impact factor: 3.327

Review 4.  Neoplastic pericardial effusion.

Authors:  Marwan M Refaat; William E Katz
Journal:  Clin Cardiol       Date:  2011-09-16       Impact factor: 2.882

Review 5.  Pericardial Disease Associated with Malignancy.

Authors:  Ryan Schusler; Shari L Meyerson
Journal:  Curr Cardiol Rep       Date:  2018-08-20       Impact factor: 2.931

6.  Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions.

Authors:  Ben Davidson; Tian-Li Wang; Ie-Ming Shih; Aasmund Berner
Journal:  Hum Pathol       Date:  2008-03-04       Impact factor: 3.466

7.  Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma.

Authors:  Lilach Kleinberg; Vivi Ann Flørenes; Martina Skrede; Hiep Phuc Dong; Søren Nielsen; Michael T McMaster; Jahn M Nesland; Ie-Ming Shih; Ben Davidson
Journal:  Virchows Arch       Date:  2006-03-16       Impact factor: 4.064

8.  Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients.

Authors:  Kan Yonemori; Hideo Kunitoh; Koji Tsuta; Tetsutaro Tamura; Yasuaki Arai; Yasuhiro Shimada; Yasuhiro Fujiwara; Yuko Sasajima; Hisao Asamura; Tomohide Tamura
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

9.  A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811).

Authors:  H Kunitoh; T Tamura; T Shibata; M Imai; Y Nishiwaki; M Nishio; A Yokoyama; K Watanabe; K Noda; N Saijo
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

10.  Breast carcinoma cells in primary tumors and effusions have different gene array profiles.

Authors:  Sophya Konstantinovsky; Yoav Smith; Sofia Zilber; Helene Tuft Stavnes; Anne-Marie Becker; Jahn M Nesland; Reuven Reich; Ben Davidson
Journal:  J Oncol       Date:  2009-08-11       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.